DCTH (Delcath Systems) Net Income (Continuing Operations): $0.53 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DCTH Delcath Systems Inc DCTH
77 GF Score
Price $16.43
GF Value $29.58
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Delcath Systems Net Income (Continuing Operations)?

Delcath Systems DCTH -0.87% 77 Net Income (Continuing Operations) is $0.53 Mil as of Jun. 2026. GuruFocus rates DCTH with a GF Score™ of 77/100 and a GF Value™ of $29.58 (Significantly Undervalued). The stock has 5 warning signs investors should review.

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Delcath Systems's Net Income (Continuing Operations) for the three months ended in Jun. 2026 was $2.67 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was $0.53 Mil.

Delcath Systems  (NAS:DCTH) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Delcath Systems Net Income (Continuing Operations) Related Terms

Delcath Systems Net Income (Continuing Operations) Historical Data

* Premium members only.

The historical data trend for Delcath Systems's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Delcath Systems Net Income (Continuing Operations) Chart

Delcath Systems Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -25.65 -36.51 -47.68 -26.39 2.70

Delcath Systems Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.70 0.83 -1.90 -1.07 2.67
DCTH
77GF Score
Delcath Systems Inc DCTH
Net Income (Continuing Operations) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Delcath Systems Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.53 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Net Income (Continuing Operations) of $0.53 Mil mean?
Delcath Systems (DCTH) has a Net Income (Continuing Operations) of $0.53 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Delcath Systems and its competitors.
Is Delcath Systems' Net Income (Continuing Operations) too high?
Delcath Systems' current Net Income (Continuing Operations) is $0.53 Mil. Overall, Delcath Systems has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Delcath Systems' Net Income (Continuing Operations) compare to CERS and CTKB?
Delcath Systems' Net Income (Continuing Operations) of $0.53 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Medical Devices & Instruments company?
A good Net Income (Continuing Operations) depends on the Medical Devices & Instruments industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Delcath Systems and its competitors. Delcath Systems's current Net Income (Continuing Operations) is $0.53 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Delcath Systems stock overvalued right now?
Based on GuruFocus' analysis, Delcath Systems (DCTH) is currently considered Significantly Undervalued. The stock's GF Value™ is $29.58, compared to a current price of $16.43 — trading 44.5% below its estimated fair value. The current Net Income (Continuing Operations) is $0.53 Mil. Delcath Systems' overall GF Score™ is 77/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Delcath Systems (DCTH), the current Net Income (Continuing Operations) is $0.53 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Delcath Systems (DCTH) Overvalued in 2026?

Based on GuruFocus' analysis, Delcath Systems stock appears to be undervalued. The current stock price of $16.43 is trading 44.5% below its estimated GF Value™ of $29.58. GuruFocus considers Delcath Systems to be Significantly Undervalued.

Key valuation signals for DCTH:

  • Net Income (Continuing Operations): $0.53 Mil
  • GF Value™: $29.58 vs. price of $16.43 (44.5% below fair value)
  • GF Score™: 77/100 with 5 warning signs

No single metric tells the full story. See the DCTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Delcath Systems Business Description

Other Exchanges DV3R:Germany
Address 566 Queensbury Avenue, Queensbury, NY, USA, 12804
Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
77GF Score

Get the complete analysis for DCTH

Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$16.43
Price
$29.58
GF Value